In order to promote the application of Astragalus polysaccharides(APS)in Ictalurus punctatus,the pharmacodynamics and safety of APS on I.punctatus were evaluated refer to SOP for clinical efficacy and safety evaluation of immunomodulators issued by the clinical trial center of new fishery drugs of the Ministry of agri-culture and rural areas.The results of phase Ⅱ clinical trial showed that the addition of APS to the feed could significantly improve the activities of total superoxide dismutase(T-SOD),catalase(CAT),lysozyme(LSZ),acid phosphatase(ACP),alkaline phosphatase(AKP)and leukocyte phagocytosis in the serum of I.punctatus.In phase Ⅲ clinical practice,it was found that APS could not only enhance the immunity of I.punctatus,im-prove its ability to resist bacterial infection,but also promote the growth of I.punctatus.The optimal addition a-mount of APS was 20 mg/kg fish weight.The clinical safety evaluation found that the daily feeding of APS 20 mg/kg fish weight was not harmful to I.punctatus.The above results showed that APS was suitable to be used as an immune enhancer in the cultivation of I.punctatus,and it was suggested that the daily addition of APS in the feed should be 20 mg/kg fish weight.
NETL
NSTL
万方数据
